{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019070","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.889541+00:00","generated_at":"2026-06-25T21:48:24.496114+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PMV Pharma reports Q1 2022 net loss of $18.4M; cash at $294.8M; ASCO presentation on PC14586","bullets":["Net loss of $18.4M for Q1 2022 vs $11.6M in Q1 2021; R&D spend increased to $11.8M.","Cash, equivalents and marketable securities totaled $294.8M as of March 31, 2022, down from $314.1M at year-end 2021.","Initial Phase 1/2 data for PC14586 (p53 Y220C reactivator) selected for oral presentation at ASCO 2022 on June 7.","Continued advancement of WIP1 inhibitor and p53 mutant pipeline programs.","Net cash used in operations was $18.0M in Q1 2022 vs $12.9M in Q1 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019070","json":"https://secwatch.observer/filing/0001564590-22-019070.json","markdown":"https://secwatch.observer/filing/0001564590-22-019070.md","text":"https://secwatch.observer/filing/0001564590-22-019070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000156459022019070/0001564590-22-019070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000156459022019070/pmvp-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:48:24.496114+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}